Peritoneum cancer
Therapeutic area
Oncology
Rare disease
No
- Definition
- A malignant neoplasm involving the peritoneum
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Peritoneum cancer
- Therapeutic area
- Oncology
- peritoneum cancer
- cancer of peritoneum
- cancer of the peritoneum
- malignant neoplasm of peritoneum
- malignant peritoneal neoplasm
- malignant peritoneum neoplasm
- peritoneal cancer
- peritoneal cavity cancer
- peritoneum cancer
- All therapeutic areas
- Oncology
- Severity
- Severe
- MONDO ID
- MONDO:0002087
- Parent condition
- MONDO:0004992
Related records
Broader conditions (8)
- Cancer
- Cancer or benign tumor
- Disease
- Disease by etiologic mechanism
- Human disease
- Neoplasm
- Neoplastic disease or syndrome
- Peritoneal neoplasm
Narrower conditions (11)
- Malignant peritoneal germ cell tumor
- Malignant peritoneal mesothelioma
- Malignant peritoneal solitary fibrous tumor
- Peritoneal carcinoma
- Peritoneal carcinomatosis
- Peritoneal serous adenocarcinoma
- Primary peritoneal carcinoma
- Primary peritoneal serous adenocarcinoma
- Primary peritoneal serous/papillary carcinoma
- Pseudomyxoma peritonei
- Round ligament malignant neoplasm
Trials (585)
- [177Lu]Ludotadipep Treatment in Patients With Metastatic Castration-resistant Prostate Cancer.
- [Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer
- [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application
- [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application_2
- 11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression
- 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- 177Lu-EB-PSMA617 in Patients With Metastatic Castration-resistant Prostate Cancer
- 177Lu-HTK03170 in mCRPC With PSMA Positive Disease
- 177Lu-LNC1011 in Patients with Metastatic Castration-resistant Prostate Cancer
- 177Lu-P17-087/177Lu-P17-088 in Patients With Metastatic Castration-resistant Prostate Cancer
- 177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia
- 177Lu-PSMA-617 Managed Access Program for mCRPC Patients
- 177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer
- 177Lu-PSMA-EB-01 in Patients With Metastatic Castration-resistant Prostate Cancer
- 177Lu-PSMA-I＆T PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer
- 177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer
- 18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies
- 3D1015 Injection for Patients With mCRPC
- 3TMPO (Triple-Tracer Strategy Against Metastatic Prostate Cancer
- 64Cu-GRIP B in Patients With Advanced Malignancies
Approved drugs (1)
Drugs in development (138)
- 8H9 131I Phase 1
- 9-aminocamptothecin Phase 2
- Abagovomab Phase 1
- Adavosertib Phase 2
- Aldesleukin Phase 2
- Alemtuzumab Phase 1
- Alisertib Phase 2
- Allopurinol Phase 2
- Alvimopan Phase 3
- Amifostine Phase 2
- Arzoxifene hydrochloride Phase 2
- Atrasentan hydrochloride Phase 2
- Avelumab Phase 1
- Belinostat Phase 2
- Bicalutamide Phase 2
- Binimetinib Phase 3
- Bosutinib Phase 1
- Bupivacaine Phase 3
- Bupivacaine hydrochloride Phase 3
- Canfosfamide hydrochloride Phase 2
Other linked drugs (2)
- Catequentinib
- Niraparib tosylate monohydrate